HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023

Noura Choudhury, MD, an oncology expert, analyzed HPN328's 35% response rate across tumors, its impact on SCLC, neuroendocrine tumors, and the management of cytokine release syndrome. Her insights suggested a transformative future for immunotherapy in addressing high unmet medical needs.


By. Noura Choudhury, MD
Date. October 31, 2023

Noura Choudhury, MD, a medical researcher specializing in oncology therapeutics, is a key figure in understanding the clinical significance of HPN328, a cutting-edge immunotherapy drug. Her expertise and experience in the field enable a comprehensive analysis of recent clinical trial data and its implications for cancer treatment.

In the interview, Dr. Noura Choudhury addresses the significant insights drawn from HPN328's clinical trial results. Highlighting the drug's remarkable confirmed response rate of 35% across diverse tumor types with a mere 1 mg priming dose, including instances of complete responses, she elucidates the potential implications for revolutionizing cancer treatment protocols.

The conversation delves into the implications of the 32% confirmed response rate, with one complete response, in patients with small cell lung cancer (SCLC). Dr. Choudhury articulates the significance of this outcome, pointing towards the potential for HPN328 to play a crucial role in the therapy for this aggressive cancer type.

Further discussions explore the promising outcomes in other neuroendocrine tumor types, with a 42% confirmed response rate, including two complete responses. Dr. Choudhury sheds light on the potential implications of these results for patients with such tumor types, suggesting a potential paradigm shift in their treatment options and prognosis.

The safety profile of HPN328 is also a significant point of discussion, with cytokine release syndrome (CRS) being the most common adverse event. Dr. Choudhury elaborates on the clinical significance of CRS in this context and emphasizes its management for patients undergoing this immunotherapy.

The interview concludes by contemplating the potential impact of HPN328 on the future of immunotherapy for patients with high unmet medical needs. Dr. Choudhury provides insights into how the positive results might shape the landscape of cancer treatment, discussing potential Phase 2 regimen selections and the anticipation of future registrational studies.

Dr. Noura Choudhury offers a comprehensive understanding of the clinical significance of HPN328's results. Her insights pave the way for understanding the implications and future prospects for patients with various cancer types.